Improved Drug Safety Needs Better Data Before AI - Qinecsa

Improved Drug Safety Needs Better Data Before AI

Applying artificial intelligence (AI) to fragmented and incomplete safety data cannot fill the gap left when the right information has not been captured during initial patient adverse event reporting. And yet, software vendors position the technology as a quick fix to safety data complexity. Although AI definitely has a role to play, it would be far better to use it to refine the data capture process, driving richer safety insights and ultimately better safety outcomes. Regulators could help ensure this with a clearer mandate for professional data collectors, says Daniel O’keeffe of Qinecsa Solutions.

Read article

Recent Articles

The Productivity Crisis That Persists Even Now: What Will It Take to Free Up PV Professionals to Assess Safety, Rather Than Coordinate Data?

Embracing quantitative signal detection methods as a smaller MAH

Real-Time Safety Signals Drive Continuous PV Insight

From Complaint Handling to Active Surveillance

Continuous Safety Surveillance for Medical Devices

Are patient outcomes getting lost in safety data complexity?

PreviousQinecsa signals next growth chapter with appointment of Alex Livingstone-Learmonth as Chief Commercial Officer

NextPharma’s operational imperatives for 2026: what next for AI, data and connected information delivery?